Clinical Trials on MEK1 Gene Mutation in Japan

Total 47 results

Pharming Technologies B.V.
Laboratory Corporation of America; CMIC Co, Ltd. Japan; Axial Biotech, Inc

Recruiting

An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

APDS Gene Mutation

Japan
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
Okayama University
Merck Sharp & Dohme LLC

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast Carcinoma

Japan
Boehringer Ingelheim

Completed

A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)

Solid Tumors, KRAS Mutation

Japan
Bayer

Completed

An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Japan
Pfizer

Recruiting

Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)

EGFR Mutation-positive Inoperable or Reccrent NSCLC

Japan
Bayer

Recruiting

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

Advanced or Recurrent Solid Tumor Harboring an NTRK Gene Fusion

Japan
Boehringer Ingelheim

Completed

A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])

Solid Tumors, KRAS Mutation

Japan
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophy

Biallelic RPE65 Mutation-associated Retinal Dystrophy

Japan
Boehringer Ingelheim

Recruiting

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Solid Tumor, KRAS Mutation

United States, Taiwan, Japan
Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
National Cancer Center, Japan
Eisai Co., Ltd.

Active, not recruiting

NCCH2006/MK010 Trial (FORTUNE Trial)

Advanced or Recurrent Solid Tumors | FGFR Gene Alterations

Japan
Biogen

Recruiting

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

United States, Canada, Spain, Australia, Germany, Italy, Japan, Korea, Republic of, United Kingdom, Belgium, Brazil, France, Poland, Sweden
Blueprint Medicines Corporation

Active, not recruiting

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Respiratory Tract Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Metastatic Lung Cancer | Antineoplastic Agents | Brain Metastases | Lung Neoplasm Malignant | EGFR... and other conditions

United States, Canada, Korea, Republic of, Japan, Taiwan
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)

Advanced Cholangiocarcinoma | FGFR2 Gene Rearrangements

United States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
Bayer

Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body (ON-TRK)

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

United States, Austria, Denmark, Germany, Italy, Norway, Spain, United Kingdom, Brazil, Russian Federation, Switzerland, Taiwan, Canada, China, Australia, Greece, Belgium, Sweden, Korea, Republic of, France, Argentina, Finland, Ireland and more
Novartis Pharmaceuticals

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Japan
Kyoto University
Osaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaborators

Completed

Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease (REBRAnD)

Familial Alzheimer Disease (FAD) | PSEN1 Mutation

Japan
Pfizer

Completed

Transthyretin Amyloidosis Outcome Survey (THAOS) (THAOS)

Transthyretin Amyloidosis | Transthyretin Gene Mutations

United States, France, Spain, Taiwan, Israel, Korea, Republic of, Denmark, Canada, Netherlands, Japan, Sweden, Brazil, Mexico, Argentina, Portugal, Belgium, Bulgaria, Cyprus, Germany, Italy, Malaysia, Romania, Saudi Arabia, Turkey, United...
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
Juntendo University
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Non-squamous Non-small-cell Lung Cancer | EGFR Activating Mutation

Japan
Taiho Oncology, Inc.

Recruiting

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4)

Advanced Cholangiocarcinoma | FGFR2 Fusions | Gene Rearrangement

United States, Korea, Republic of, Spain, Japan, Portugal, Italy, China, Argentina, Brazil, Poland, Australia
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
Biogen
Ionis Pharmaceuticals, Inc.

Active, not recruiting

Long-Term Evaluation of BIIB067 (Tofersen)

ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

United States, Canada, Italy, Belgium, New Zealand, Japan, France, Germany, United Kingdom
AstraZeneca
Daiichi Sankyo Co., Ltd.

Active, not recruiting

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01)

Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

Italy, Spain, United States, France, Korea, Republic of, Japan, Canada, Denmark, Belgium
Bayer

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

Hong Kong, United States, Taiwan, Spain, Belgium, China, Japan, France, Korea, Republic of, Singapore, Poland, Israel, Italy, Netherlands, Portugal, Brazil
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, United Kingdom, France, Italy, China, Korea, Republic of, Canada, Japan, Netherlands
AstraZeneca

Completed

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

HER2-ve Metastatic Breast Cancer | Germline BRCA1/2 Mutations | Somatic BRCA1/2 Mutations

Italy, Spain, Poland, Taiwan, Canada, France, Germany, Korea, Republic of, Hungary, Japan, Russian Federation, Turkey, United Kingdom, United States, Bulgaria
Pfizer

Terminated

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

Locally Advanced or Metastatic Solid Tumors | Genes, BRCA 1

United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
Nobelpharma

Completed

Efficacy Confirmation Study of NPC-09

GNE Myopathy | Nonaka Disease | Distal Myopathy With Rimmed Vacuoles (DMRV) | Hereditary Inclusion Body Myopathy (hIBM)

Japan
Amgen

Recruiting

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Advanced Solid Tumors | Kirsten Rat Sarcoma (KRAS) pG12C Mutation

United States, Italy, Taiwan, Spain, United Kingdom, Australia, Austria, Germany, Belgium, Japan, Netherlands, Korea, Republic of, Canada
AstraZeneca

Completed

Europe-Japan Diagnostic Study for EGFR Testing (ASSESS)

EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.

Italy, Spain, United Kingdom, Sweden, Japan, Netherlands, Germany, France
Haihe Biopharma Co., Ltd.

Recruiting

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

C-Met Exon 14 Mutation

China, Japan, United States
Novartis Pharmaceuticals

Terminated

Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. (ReTHINK)

Myelofibrosis With High Molecular Risk Mutations

Belgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States, Japan, Taiwan, Spain, Australia, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Poland, United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation

Taiwan, Poland, Serbia, United States, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Romania, Spain, Sweden, United Kingdom
Novartis Pharmaceuticals

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations (MASter-1)

NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations

Spain, France, United States, Canada, Japan, United Kingdom, Turkey, Czechia, Italy
Taiho Oncology, Inc.

Recruiting

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) (REZILIENT3)

Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation

United States, Spain, Canada, Italy, Israel, Japan, United Kingdom, Korea, Republic of, Germany, France, Turkey, Belgium, Netherlands, Philippines, Poland, Singapore
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Astellas Pharma Global Development, Inc.

Approved for marketing

Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)

Acute Myeloid Leukemia (AML) | FMS-like Tyrosine Kinase-3 (FLT3) Mutations

United States, Canada, Japan
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, France, Australia, Italy, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
ArriVent BioPharma, Inc.
Allist Pharmaceuticals, Inc.

Recruiting

Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | EGFR Exon 20 Mutations

United States, Australia, Spain, France, Italy, China, Japan, Korea, Republic of, Malaysia, Netherlands, Philippines, Singapore, Taiwan, Thailand, Brazil, Israel, United Kingdom
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain
Seagen Inc.

Active, not recruiting

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Urologic Neoplasms | Uterine Cervical Neoplasms | Uterine Neoplasms | Carcinoma, Non-Small-Cell Lung | Biliary Tract Neoplasms | HER2 Mutations Breast Neoplasms

United States, United Kingdom, Spain, Korea, Republic of, Italy, Belgium, Germany, Japan, Netherlands, Poland

Clinical Trials on MEK1 Gene Mutation in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations